Replies to post #746821 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The damages will be focussed on the 40 million shares. Since that is a 4 months dilution NWBO I think its more like $1.5 or so per share in damages. But that's just a guess.

The 40M shares were most all sold under $.50, eyeball estimate at about $.25 average (exhibit 2 of the SAC). The shares were sold by NWBO at a price based on the close, and that price was allegedly reduced by the spoof, so that caused NWBO a loss. The complaint lists the asserted price decline for each spoof (exhibit 2 of the SAC) and it is almost always under 10%, and often under 5%.

Care to try some math? 40M shares at $.25 and a 10% damage on each. That comes out to about $1M total.

[Investor082]

This was always a distraction. Everything depends on relentless execution and getting investors excited about the future. They haven’t been able to do that in the last decade or so. Playing a victim card and excuses is never a winning strategy! Even today, the focus is on the lawsuit and not what’s coming post approval in terms of how they can accelerate regulatory approvals and reimbursements in other jurisdictions (particularly US, which is almost 20X of UK, and over 50% of the SAM), clinical trials, etc. They have no money and haven’t been able to convince big pharma to inject cash in NWBO, 4.5 years since data lock. Thats the sad reality!

Again, it will all boil down to significant cash injection from big pharma. Outside that, the stock will continue to lose value except a brief spike at the UK approval, which won’t sustain for long. Dilution will accelerate over the next couple of years and shorts will take advantage given the lethargic management crew and the cash situation.

One can also follow Phunware case. The stock is down from the date of ruling.

[Kam8]

LP just doesn't accept Settlement and go discovery🤞😆🤞, I don't think MMs want discovery so they might accept big money for settlement. 😆😆